Connection

Marc Bonten to Serogroup

Back to Details
This is a "connection" page, showing publications Marc Bonten has written about Serogroup.
Marc Bonten
Connection Strength
0.149
Serogroup
  1. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. Vaccine. 2019 07 09; 37(30):4147-4154.
    View in: PubMed
    Score: 0.040
  2. The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study. Clin Infect Dis. 2018 06 18; 67(1):42-49.
    View in: PubMed
    Score: 0.038
  3. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 2017 12 18; 35(51):7078.
    View in: PubMed
    Score: 0.036
  4. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Vaccine. 2017 03 01; 35(9):1266-1272.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.